Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Pramlintide and Metreleptin in Obesity
NCT00819234Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2008
- Primary completion
- Oct 2009
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pramlintide and metreleptin in obesity (4 arms), sponsored by AstraZeneca. Primary endpoint: LS Mean Percent Change in Body Weight From Original Study Baseline at 52 weeks. Started Nov 2008; status: completed.
02
Drugs
pramlintidemetreleptin
03
Conditions
obesity
Beyond the preview
Go deeper on NCT00819234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00819234.